- $55.93m
- $64.05m
- $36.35m
- 48
- 30
- 63
- 44
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 4.3 | ||
Price to Tang. Book | 4.3 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 1.48 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -56.08% | ||
Return on Equity | -118.5% | ||
Operating Margin | -58.51% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 24.95 | 41 | 43.17 | 34.69 | 36.35 | 38.92 | 43.45 | 10.06% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in intensive care (ICU) and cardiac surgery using blood purification via its proprietary polymer adsorption technology. The Company’s flagship product, CytoSorb, is an extracorporeal cytokine absorber, designed to reduce the cytokine storm or cytokine release syndrome that could otherwise cause massive inflammation, organ failure and death in common critical illnesses, such as sepsis, burn injury, trauma, lung injury, cytokine release syndrome due to cancer immunotherapy, and pancreatitis. Its other products include CytoSorb, animal-targeted VetResQ, DrugSorb-ATR and ECOS-300CY. Its other product candidates under development, including CytoSorb XL, BetaSorb, ContrastSorb, DrugSorb, HemoDefend-RBC, HemoDefend-BGA, K+ontrol, and others consist of a cartridge containing adsorbent, porous polymer beads, although the polymers used in these devices are physically different.
Directors
- Al Kraus NEC (75)
- Vincent Capponi PRE (62)
- Phillip Chan CEO (49)
- Kathleen Bloch CFO (65)
- Efthymios Deliargyris CSO (52)
- Michael Bator IND (56)
- Edward Jones IND (71)
- Alan Sobel IND (59)
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- October 28th, 2014
- Public Since
- June 17th, 2005
- No. of Shareholders
- 11,100
- No. of Employees
- 186
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market
- Shares in Issue
- 54,830,146

- Address
- 305 COLLEGE ROAD EAST, PRINCETON, 08540
- Web
- https://cytosorbents.com/
- Phone
- +1 9733298885
- Auditors
- Withum- Smith & Brown
Upcoming Events for CTSO
Q1 2025 Cytosorbents Corp Earnings Release
Cytosorbents Corp Annual Shareholders Meeting
Similar to CTSO
Accelerate Diagnostics
NASDAQ Capital Market
Adagio Medical Holdings
NASDAQ Capital Market
Adapthealth
NASDAQ Capital Market
Aethlon Medical
NASDAQ Capital Market
Agape ATP
NASDAQ Capital Market
FAQ
As of Today at 19:11 UTC, shares in Cytosorbents are trading at $1.02. This share price information is delayed by 15 minutes.
Shares in Cytosorbents last closed at $1.02 and the price had moved by over the past 365 days. In terms of relative price strength the Cytosorbents share price has underperformed the S&P500 Index by -16.58% over the past year.
The overall consensus recommendation for Cytosorbents is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreCytosorbents does not currently pay a dividend.
Cytosorbents does not currently pay a dividend.
Cytosorbents does not currently pay a dividend.
To buy shares in Cytosorbents you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.02, shares in Cytosorbents had a market capitalisation of $55.93m.
Here are the trading details for Cytosorbents:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CTSO
Based on an overall assessment of its quality, value and momentum Cytosorbents is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Cytosorbents is $7.00. That is 586.27% above the last closing price of $1.02.
Analysts covering Cytosorbents currently have a consensus Earnings Per Share (EPS) forecast of -$0.30 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cytosorbents. Over the past six months, its share price has underperformed the S&P500 Index by -13.84%.
As of the last closing price of $1.02, shares in Cytosorbents were trading +2.72% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Cytosorbents PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.02.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Cytosorbents' management team is headed by:
- Al Kraus - NEC
- Vincent Capponi - PRE
- Phillip Chan - CEO
- Kathleen Bloch - CFO
- Efthymios Deliargyris - CSO
- Michael Bator - IND
- Edward Jones - IND
- Alan Sobel - IND